NCT07234162 2025-11-18A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)Dizal PharmaceuticalsPhase 3 Recruiting218 enrolled
NCT01482962 2018-07-31Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaTakedaPhase 3 Completed271 enrolled 25 charts